Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma
Open Access
- 25 November 2014
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 100 (2), e63-e67
- https://doi.org/10.3324/haematol.2014.112557
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Association of response endpoints with survival outcomes in multiple myelomaLeukemia, 2013
- Living With Advanced But Stable Multiple Myeloma: A Study of the Symptom Burden and Cumulative Effects of Disease and Intensive (Hematopoietic Stem Cell Transplant-Based) Treatment on Health-Related Quality of LifeJournal of Pain and Symptom Management, 2013
- Health‐related quality of life and disease‐specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population‐based study using the PROFILES registryEuropean Journal of Haematology, 2012
- Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experienceLeukemia & Lymphoma, 2012
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Responsiveness and minimal important score differences in quality‐of‐life questionnaires: a comparison of the EORTC QLQ‐C30 cancer‐specific questionnaire to the generic utility questionnaires EQ‐5D and 15D in patients with multiple myelomaEuropean Journal of Haematology, 2011
- Unmet supportive care needs, psychological well‐being and quality of life in patients living with multiple myeloma and their partnersPsycho‐Oncology, 2010
- Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone diseaseLeukemia, 2010
- Bortezomib is associated with better health‐related quality of life than high‐dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX studyBritish Journal of Haematology, 2008
- Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myelomaEuropean Journal of Haematology, 2008